BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long term lenalidomide therapy in previously untreated patients with multiple myeloma
Menée sur 72 patients atteints d'un myélome multiple, cette étude présente les résultats à long terme de l'essai BiRd évaluant la combinaison clarithromycine, lénalidomide et dexaméthasone (durée médiane de suivi : 6,6 ans)
The combination of clarithromycin, lenalidomide and dexamethasone (BiRd) was evaluated as therapy for treatment-naïve symptomatic multiple myeloma (MM), with overall response at 2 years of 90%. We reviewed the long term follow-up of initial BiRd therapy. Seventy-two patients were given dexamethasone 40mg weekly, clarithromycin 500mg twice daily, and lenalidomide 25mg daily on days 1-21, of a 28 day cycle. After a median follow-up of 6.6 years, overall response rates were 93%, with a very good partial response or better of 68%. Median progression free survival was 49 months. Evaluation for the development of second primary malignancies (SPM) was conducted, and no increase in incidence was noted in our cohort of patients who received front-line immunomodulatory therapy. BiRd remains a highly potent and safe regimen for front-line therapy in patients with MM without apparent increase in risk of SPMs. This trial was registered at www.clinicaltrials.gov as #NCT00151203.